ALLO
Allogene Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
1.45
▼ 0.05 (3.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.50
Prev close
1.50
Day high
1.50
Day low
1.43
Volume
4.65M
Market cap
$504.42M
P/E (TTM)
—
52W range
1.04 – 4.46
Day trading desk
Gap from prior close
0.00%
Prior close 1.50
VWAP
1.46
-0.78% from price
Relative volume
1.51×
Unusually busy
Session range
9.09%
1.43 – 1.56
Position in range
15%
Near session low
ATR (14D)
0.08
5.22% of price
Prior day high
1.52
PDH
Prior day low
1.45
PDL
Bid / ask spread
—
Quote not published
Session volume
8.97M
Avg 5.93M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.88%
-11.8%
1M
-25.89%
-27.0%
3M
-31.13%
-35.7%
6M
-44.27%
-62.5%
YTD
+6.57%
-7.7%
1Y
+9.77%
-6.6%
3Y
-53.94%
-136.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ALLO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+8.42K
Net buying
Buy transactions
1
47.70K shares
Sell transactions
2
39.28K shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.8 : 1
Mixed
Insider-held shares
38.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 21, 26 | DOUGLAS EARL MARTIN General Counsel |
SELL | 29.70K | $62.96K | Direct |
| Jun 18, 26 | KAZAM JOSHUA A Director |
— | 47.70K | — | Direct |
| Apr 21, 26 | YOSHIYAMA ANNIE Officer |
SELL | 9.59K | $22.14K | Direct |
| Mar 31, 26 | BENESKI BENJAMIN MACHINAS Chief Technology Officer |
SELL | 2.87K | $7.17K | Direct |
| Mar 16, 26 | CHANG DAVID D Chief Executive Officer |
SELL | 47.76K | $117.97K | Direct |
| Mar 16, 26 | BENESKI BENJAMIN MACHINAS Chief Technology Officer |
SELL | 4.83K | $11.94K | Direct |
| Mar 2, 26 | BENESKI BENJAMIN MACHINAS Chief Technology Officer |
SELL | 7.13K | $18.54K | Direct |
| Feb 2, 26 | DOUGLAS EARL MARTIN General Counsel |
SELL | 22.90K | $40.30K | Direct |
| Feb 2, 26 | CHANG DAVID D Chief Executive Officer |
SELL | 95.27K | $171.48K | Direct |
| Feb 2, 26 | PARKER GEOFFREY M Chief Financial Officer |
SELL | 24.00K | $42.24K | Direct |
| Feb 2, 26 | YOSHIYAMA ANNIE Officer |
SELL | 4.17K | $7.17K | Direct |
| Feb 2, 26 | ROBERTS ZACHARY Officer |
SELL | 35.70K | $63.19K | Direct |
| Feb 2, 26 | BENESKI BENJAMIN MACHINAS Chief Technology Officer |
SELL | 7.55K | $13.06K | Direct |
| Jan 21, 26 | ROBERTS ZACHARY Officer |
SELL | 26.27K | $40.98K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BELLDEGRUN ARIE S |
Director | 11.01M | Stock Award(Grant) |
BENESKI BENJAMIN MACHINAS |
Chief Technology Officer | 195.34K | Sale |
CHANG DAVID D |
Chief Executive Officer | 8.06M | Sale |
DOUGLAS EARL MARTIN |
General Counsel | 488.27K | Sale |
HUMER FRANZ B |
Director | 307.51K | Sale |
KAZAM JOSHUA A |
Director | 398.46K | Conversion of Exercise of derivative security |
MOORE TIMOTHY L. |
Chief Technology Officer | 250.71K | Sale |
PARKER GEOFFREY M |
Chief Financial Officer | 1.25M | Sale |
ROBERTS ZACHARY |
Officer | 581.17K | Sale |
YOSHIYAMA ANNIE |
Officer | 124.52K | Sale |
Fundamentals
Market cap$504.42M
Enterprise value$250.82M
Revenue (TTM)$4.64M
Gross profit$-117.88M
EBITDA$-168.65M
Net income$-165.49M
EPS (TTM)$-0.64
Free cash flow$-63.46M
Total cash$332.60M
Total debt$79.01M
Book value / share$1.26
Shares outstanding345.49M
Float281.13M
Short % of float19.09%
Dividend yield0.00%
Beta (5Y)0.56
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.24
PEG ratio—
Price / sales—
Price / book1.16
EV / revenue54.06
EV / EBITDA-1.49
Gross margin0.00%
Operating margin-1011.21%
Profit margin0.00%
Return on equity-42.39%
Return on assets-22.08%
Debt / equity18.11
Current ratio10.72
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $22.00K | $95.00K | $156.00K | — | -100.0% |
| Operating revenue | $0 | $22.00K | $95.00K | $156.00K | — | -100.0% |
| Research & development | $150.15M | $192.30M | $242.91M | $256.39M | — | -21.9% |
| Selling, general & admin | $56.78M | $65.20M | $71.67M | $79.31M | — | -12.9% |
| Total operating expense | $206.93M | $257.50M | $314.59M | $335.69M | — | -19.6% |
| Operating income | -$206.93M | -$257.48M | -$314.49M | -$335.54M | — | +19.6% |
| Net interest income | $18.21M | $19.97M | $18.31M | $4.57M | — | -8.8% |
| Pre-tax income | -$190.89M | -$257.15M | -$327.26M | -$340.41M | — | +25.8% |
| Tax provision | $0 | $443.00K | $0 | — | $0 | -100.0% |
| Net income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | — | +25.9% |
| Net income to common | -$190.89M | -$257.59M | -$327.26M | -$340.41M | — | +25.9% |
| Basic EPS | -0.87 | -1.32 | -2.09 | -2.32 | — | +34.1% |
| Diluted EPS | -0.87 | -1.32 | -2.09 | -2.32 | — | +34.1% |
| EBIT | -$189.81M | -$256.97M | -$327.26M | -$335.54M | — | +26.1% |
| EBITDA | -$177.45M | -$243.33M | -$313.07M | -$321.24M | — | +27.1% |
| Basic shares | 220.62M | 194.81M | 156.93M | 143.15M | — | +13.2% |
| Diluted shares | 220.62M | 194.81M | 156.93M | 143.15M | — | +13.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $51.69M | $75.22M | $83.16M | $61.90M | -31.3% |
| Cash & short-term investments | $250.21M | $292.48M | $448.70M | $517.32M | -14.5% |
| Total current assets | $257.75M | $303.39M | $459.12M | $528.82M | -15.0% |
| Property, plant & equipment | $112.73M | $131.26M | $163.18M | $196.43M | -14.1% |
| Total assets | $415.90M | $548.71M | $642.84M | $821.58M | -24.2% |
| Total current liabilities | $32.51M | $35.52M | $37.08M | $53.73M | -8.5% |
| Total debt | $83.25M | $90.76M | $95.12M | $101.12M | -8.3% |
| Total liabilities | $123.36M | $126.53M | $130.60M | $154.70M | -2.5% |
| Retained earnings | -$2.01B | -$1.82B | -$1.56B | -$1.23B | -10.5% |
| Shareholder equity | $292.54M | $422.18M | $512.23M | $666.88M | -30.7% |
| Working capital | $225.24M | $267.86M | $422.04M | $475.10M | -15.9% |
| Net tangible assets | $292.54M | $422.18M | $512.23M | $666.88M | -30.7% |
| Shares issued | 229.41M | 212.21M | 168.64M | 144.44M | +8.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | +25.9% |
| Depreciation & amortisation | $12.36M | $13.64M | $14.20M | $14.29M | -9.4% |
| Stock-based compensation | $37.64M | $51.74M | $65.95M | $83.60M | -27.3% |
| Change in working capital | -$10.88M | -$24.80M | -$21.31M | $3.90M | +56.1% |
| Operating cash flow | -$149.25M | -$200.30M | -$237.73M | -$220.52M | +25.5% |
| Capital expenditure | -$386.00K | -$694.00K | -$1.52M | -$5.19M | +44.4% |
| Investing cash flow | $95.56M | $75.69M | $163.29M | $106.16M | +26.3% |
| Financing cash flow | $30.16M | $116.67M | $95.69M | $2.95M | -74.2% |
| Free cash flow | -$149.63M | -$200.99M | -$239.25M | -$225.71M | +25.6% |
| End cash position | $61.98M | $85.51M | $93.45M | $72.20M | -27.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.64M | $0 | $0 | $0 | $0 | — |
| Operating revenue | $4.64M | $0 | $0 | $0 | $0 | — |
| Research & development | $30.72M | $32.00M | $28.63M | $31.16M | $40.16M | -4.0% |
| Selling, general & admin | $20.84M | $14.09M | $13.77M | $13.74M | $14.28M | +47.9% |
| Total operating expense | $51.56M | $46.09M | $42.40M | $44.90M | $54.44M | +11.9% |
| Operating income | -$46.92M | -$46.09M | -$42.40M | -$44.90M | -$54.44M | -1.8% |
| Net interest income | $4.30M | $3.27M | $3.35M | $3.58M | $5.92M | +31.5% |
| Pre-tax income | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -0.2% |
| Net income | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -0.2% |
| Net income to common | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -0.2% |
| Basic EPS | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 | +27.8% |
| Diluted EPS | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 | +27.8% |
| EBIT | -$42.33M | -$42.31M | -$38.50M | -$41.06M | -$50.67M | -0.1% |
| EBITDA | -$39.69M | -$39.44M | -$35.44M | -$37.96M | -$47.57M | -0.6% |
| Basic shares | 328.93M | 240.29M | 226.03M | 222.04M | 218.93M | +36.9% |
| Diluted shares | 328.93M | 240.29M | 226.03M | 222.04M | 218.93M | +36.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.63M | $30.31M | $51.69M | $37.81M | $52.33M | +27.4% |
| Cash & short-term investments | $332.60M | $266.89M | $250.21M | $252.19M | $273.12M | +24.6% |
| Total current assets | $340.00M | $273.29M | $257.75M | $260.72M | $282.65M | +24.4% |
| Property, plant & equipment | $105.12M | $108.84M | $112.73M | $116.83M | $120.82M | -3.4% |
| Total assets | $550.09M | $395.96M | $415.90M | $439.77M | $470.59M | +38.9% |
| Total current liabilities | $31.73M | $28.33M | $32.51M | $31.83M | $31.68M | +12.0% |
| Total debt | $70.35M | $72.63M | $83.25M | $77.13M | $79.24M | -3.1% |
| Total liabilities | $113.92M | $117.08M | $123.36M | $124.44M | $126.03M | -2.7% |
| Retained earnings | -$2.10B | -$2.05B | -$2.01B | -$1.97B | -$1.93B | -2.1% |
| Shareholder equity | $436.18M | $278.88M | $292.54M | $315.33M | $344.56M | +56.4% |
| Working capital | $308.27M | $244.96M | $225.24M | $228.89M | $250.98M | +25.8% |
| Net tangible assets | $436.18M | $278.88M | $292.54M | $315.33M | $344.56M | +56.4% |
| Shares issued | 345.35M | 244.82M | 229.41M | 223.16M | 220.13M | +41.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | — | -0.2% |
| Depreciation & amortisation | $2.65M | $2.87M | $3.06M | $3.10M | $3.11M | — | -7.8% |
| Stock-based compensation | $12.44M | $8.27M | $8.13M | $8.65M | $8.69M | — | +50.4% |
| Change in working capital | $469.00K | $18.37M | -$202.00K | -$145.00K | -$2.24M | — | -97.4% |
| Operating cash flow | -$32.00M | -$12.91M | -$27.60M | -$29.69M | -$39.03M | — | -147.8% |
| Capital expenditure | -$150.00K | -$9.00K | — | -$243.00K | -$44.00K | -$99.00K | -1,566.7% |
| Investing cash flow | -$147.56M | -$29.59M | $33.61M | $11.94M | $43.84M | — | -398.7% |
| Financing cash flow | $187.87M | $21.12M | $7.86M | $3.24M | $5.07M | — | +789.5% |
| Free cash flow | -$32.15M | -$12.92M | -$27.60M | -$29.93M | -$39.07M | — | -148.8% |
| End cash position | $48.92M | $40.60M | $61.98M | $48.11M | $62.62M | — | +20.5% |
Options analytics
Put / call volume
0.20
Call-heavy session
Put / call open interest
0.01
Positioning, not flow
Max pain
0.50
-65.8% from spot
ATM implied vol
173.4%
Nearest strike to spot
Skew (10% OTM)
+39.1%
Puts bid over calls
Call volume
25
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
2.00
1.64K contracts
Heaviest put OI
2.00
9 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.15 | -0.13 | +12.2% |
| Mar 2026 | -0.18 | -0.18 | 0.0% |
| Dec 2025 | -0.22 | -0.17 | +22.5% |
| Sep 2025 | -0.23 | -0.19 | +18.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.14 | 7 | $2.00K | 0.0% |
| Next quarter | -0.14 | 7 | $2.00K | 0.0% |
| Current year | -0.59 | 7 | $3.40M | 0.0% |
| Next year | -0.65 | 6 | $12.09M | +255.5% |
Analyst targets & ownership
Mean target$9.00
High target$14.00
Low target$4.00
Implied upside520.69%
Analyst count9
ConsensusNONE
Strong buy / Buy3 / 8
Hold1
Sell / Strong sell0 / 0
Held by insiders11.03%
Held by institutions82.60%
Institutions holding279
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.58
-8.46% from price
SMA 20
1.66
-11.84% from price
SMA 50
1.86
-21.58% from price
SMA 100
1.92
-24.59% from price
SMA 200
1.99
-26.77% from price
EMA 12
1.59
-8.88% from price
EMA 26
1.70
-14.68% from price
EMA 50
1.80
-19.51% from price
RSI (14)
23.2
Oversold
MACD (12,26,9)
-0.11
Hist -0.01
ATR (14)
0.08
5.19% of price
Realised vol 30D
43.2%
Annualised
Bollinger upper
1.84
20, 2σ
Bollinger lower
1.47
20, 2σ
50 / 200 cross
Death
1.86 vs 1.99
Trend bias
Below 200
-26.77%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.12
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
43.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-52.3%
Peak to trough
Max drawdown 5Y
-96.1%
Peak to trough
ATR 14
0.08
5.19% of price
Beta (reported)
0.56
5Y monthly, from filing
Short interest
Shares short
59.60M
Prior 58.95M
Change vs prior
+1.1%
Shorts adding
% of float
19.09%
Elevated
% of shares out
17.25%
Against total outstanding
Days to cover
11.7
Crowded exit
Float
281.13M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 16, 26 | JP Morgan | UPGRADE | Underweight | Neutral |
| Apr 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 15, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Apr 14, 26 | Bernstein | MAINTAINED | Market Perform | Market Perform |
| Apr 14, 26 | Argus Research | MAINTAINED | Market Perform | Market Perform |
| Apr 14, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 14, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Apr 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 13, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 13, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jan 9, 26 | Citizens | UPGRADE | Market Perform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-02
Periodic Financial Reports
10-Q · 2026-08-12
Proxy Statements
DEFA14A · 2026-05-28
Proxy Statements
DEFA14A · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-30
Proxy Statements
PRE 14A · 2026-04-20
Corporate Changes & Voting Matters
8-K · 2026-04-15
Headlines
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Stocktwits · 22d ago
Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
MT Newswires · 22d ago
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Zacks · 26d ago
Allogene Therapeutics CFO Geoffrey Parker to Retire
MT Newswires · 35d ago
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive · 35d ago
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
GlobeNewswire · 35d ago
Allogene Therapeutics Announces Participation in September Investor Conference
GlobeNewswire · 37d ago
Allogene (ALLO) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.